Publications by authors named "M Conron"
Background: Lung cancer in Australia contributes 9% of all new cancer diagnoses and is the leading cause of cancer death and burden. Clinical practice guidelines provide evidence-based treatment recommendations for best practice management. We aimed to determine the extent of delivery of guideline-concordant treatment (GCT) and to identify modifiable variables influencing receipt of GCT and survival.
View Article and Find Full Text PDFArticle Synopsis
- Cardiopulmonary complications in connective tissue diseases (CTDs) like pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) significantly impact patient health and survival rates.
- Multidisciplinary meetings can enhance diagnostic precision and treatment strategies for these conditions.
- The review covers existing literature on these meetings in relation to CTD-ILD and PAH, along with insights from the authors' own experience at a specialized medical center.
Objectives: To report stage-specific patterns of treatment and the influence of management and treatment type on survival rates for people newly diagnosed with small cell lung cancer (SCLC).
Design: Cross-sectional patterns of care study; analysis of data prospectively collected for the Victorian Lung Cancer Registry (VLCR).
Setting, Participants: All people diagnosed with SCLC in Victoria during 1 April 2011 - 18 December 2019.
Objectives: To evaluate short-term change in oxygenation and feasibility of physiotherapy-assisted prone or modified prone positioning in awake, ward-based patients with COVID-19.
Design: Retrospective observational cohort study.
Setting: General wards, single-centre tertiary hospital in Australia.
Introduction: Multidisciplinary Meetings (MDM) are recommended in routine lung cancer care, however its broader impacts demand further evaluation. We assessed the drivers and impacts of MDM presentation in the Victorian Lung Cancer Registry (VLCR).
Methods: We examined the effect of MDM presentation on receipt of treatment and survival in VLCR patients diagnosed between 2011 and 2020.